Sorbent Gets $36 Million To Fund Phase II Program In Congestive Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
With input from new investor Novartis Venture Fund, the biotech will move its lead compound from chronic kidney disease into the potentially more lucrative heart failure space.